GSK's RSV Vaccine Gains Key FDA Approval for Younger Adults, Intensifying Competition for Moderna
MRNA has more than doubled off its 52-week low of $22.28.
Summary
GSK has received FDA approval to expand the use of its RSV vaccine, Arexvy, to include adults aged 18 to 49 who are at increased risk of lower respiratory tract disease. This significantly broadens the addressable market for GSK's vaccine, which was previously approved for older adults. This development intensifies competition for Moderna's mRESVIA and Pfizer's Abrysvo in the RSV vaccine market, particularly in this newly approved younger adult demographic, which GSK estimates includes 21 million at-risk individuals. The expanded approval for a key competitor could pressure Moderna's future market share and revenue projections for its own RSV vaccine.
At the time of this announcement, MRNA was trading at $53.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.1B. The 52-week trading range was $22.28 to $59.55. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.